Bruce Carter - Dr Reddys Non-Executive Independent Director
| RDY Stock | USD 70.92 0.57 0.80% |
Director
Dr. Bruce L. A. Carter, Ph.D., serves as a NonExecutive Independent Director of the Company. Dr. Bruce L A Carter was the Chairman of the Board and Chief Executive Offi cer of ZymoGenetics Inc., USA. He has also served as the Corporationrationrate Executive Vice President and Chief Scientifi c Offi cer for Novo Nordisk AS. Dr. Carter held various positions of increasing responsibility at G.D. Searle Co., Limited. He was a lecturer at Trinity College, University of Dublin, from 1975 to 1982. Dr. Carter holds directorship in Enanta Pharmaceutical Inc., Mirati Therapeutics Inc., Accelerator Corporation and TB Alliance, all in the US and our whollyowned subsidiary, Aurigene Discovery Technologies Limited, in India since 2008.
| Age | 77 |
| Tenure | 16 years |
| Professional Marks | Ph.D |
| Address | 8-2-337, Road No. 3, Hyderabad, India, 500034 |
| Phone | 91 40 4900 2900 |
| Web | https://www.drreddys.com |
Dr Reddys Management Efficiency
The company has Return on Asset of 0.1238 % which means that on every $100 spent on assets, it made $0.1238 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2139 %, implying that it generated $0.2139 on every 100 dollars invested. Dr Reddys' management efficiency ratios could be used to measure how well Dr Reddys manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to rise to 0.38 in 2024, whereas Return On Tangible Assets are likely to drop 0.11 in 2024. At this time, Dr Reddys' Other Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 15.4 B in 2024, whereas Total Assets are likely to drop slightly above 206.1 B in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Robert Nostrand | Intracellular Th | 61 | |
| John Freund | Collegium Pharmaceutical | 64 | |
| Gerald Carlson | Phibro Animal Health | 75 | |
| Paul Mitchell | Alkermes Plc | 64 | |
| John Longenecker | Pacira Pharmaceuticals | 70 | |
| Gary Costley | Prestige Brand Holdings | 55 | |
| Gino Santini | Collegium Pharmaceutical | 61 | |
| Andreas Wicki | Pacira Pharmaceuticals | 59 | |
| Georges Gemayel | Supernus Pharmaceuticals | 58 | |
| Wendy Dixon | Alkermes Plc | 62 | |
| Lynda Reid | Evotec SE ADR | N/A | |
| Alain Schreiber | Eagle Pharmaceuticals | 58 | |
| Edward Kay | Eagle Pharmaceuticals | N/A | |
| Charles Newhall | Supernus Pharmaceuticals | 73 | |
| Frederick Hudson | Supernus Pharmaceuticals | 72 | |
| Michael Graves | Eagle Pharmaceuticals | 61 | |
| Dennis Walsh | Deciphera Pharmaceuticals LLC | 50 | |
| Steven Ratoff | Eagle Pharmaceuticals | 81 | |
| John Siebert | Supernus Pharmaceuticals | 78 | |
| James Jenness | Prestige Brand Holdings | 73 | |
| Floyd Bloom | Alkermes Plc | 80 | |
Management Performance
| Return On Equity | 0.21 | ||||
| Return On Asset | 0.12 |
Dr Reddys Laboratories Leadership Team
Elected by the shareholders, the Dr Reddys' board of directors comprises two types of representatives: Dr Reddys inside directors who are chosen from within the company, and outside directors, selected externally and held independent of RDY. The board's role is to monitor Dr Reddys' management team and ensure that shareholders' interests are well served. Dr Reddys' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dr Reddys' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MARC KIKUCHI, Chief Executive Officer, North America Generics | ||
| Venkata MBA, CEO Council | ||
| Leo Puri, Non-Executive Independent Director | ||
| Sandeep Poddar, Compliance Officer, Company Secretary | ||
| Satish Reddy, Co-Chairman of the Board | ||
| Kedar Upadhye, IR Contact Officer | ||
| Samiran Das, Executive Vice President Head - FTO and GGPM | ||
| Patrick Aghanian, Chief Executive Officer, European Generics | ||
| Amit Biswas, Executive Vice President - Integrated Product Development | ||
| Ravi Bhoothalingam, Non-Executive Independent Director | ||
| Sanjay BTech, Global VP | ||
| Prasad Menon, Lead Non-Executive Independent Director | ||
| K Rao, Sr. Vice President & Head – Chemical Technical Operations (CTO) | ||
| K Krishnan, Additional Independent Director | ||
| Shikha Sharma, Non-Executive Independent Director | ||
| Omkar Goswami, Non-Executive Independent Director | ||
| Bharat Doshi, Non-Executive Independent Director | ||
| Gunupati BE, MD CoChairman | ||
| Raymond Vre, Global Head of Biologics | ||
| Raghav Chari, Senior Vice President - Proprietary Products | ||
| Bruce Carter, Non-Executive Independent Director | ||
| Umang Vohra, Executive Vice President Head - North America Generics | ||
| M Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets) | ||
| Parag Agarwal, Chief Financial Officer - Designate | ||
| Cartikeya Reddy, Senior Vice President Head - Biologics | ||
| Archana Bhaskar, Chief Human Resource Officer | ||
| Erez MBA, CEO Council | ||
| MS BTech, Chairman Council | ||
| Deepak Sapra, Global Head of Pharmaceutical Services and Active Ingredients | ||
| Penny Wan, Additional Independent Director | ||
| G Prasad, Co-Chairman of the Board, Chief Executive Officer, Managing Director | ||
| P Yugandhar, Global Head of Supply Chain | ||
| Hans Hasler, Additional Independent Director | ||
| Sauri Gudlavalleti, Global Head of Integrated Product Development Organization | ||
| YUGANDHAR PUVVALA, Global Head of Supply Chain | ||
| Alok Sonig, Senior Vice President & India Business Head (Generics) | ||
| K Singh, Chief Compliance Officer, Company Secretary | ||
| Allan Oberman, Non-Executive Independent Director | ||
| J Ramachandran, Executive Vice President-Management Systems and Corporate Initiatives | ||
| Abhijit Mukherjee, COO | ||
| Anil Namboodiripad, Global Head of Proprietary Products | ||
| Saumen Chakraborty, President, Chief Financial Officer and Global Head of ITBPE, Legal and Compliance and FMCRE | ||
| SANJAY SHARMA, Global Head of Manufacturing | ||
| Sridar Iyengar, Non-Executive Independent Director | ||
| Ganadhish Kamat, Executive Vice President and Global Head-Quality | ||
| Sripada Chandrasekhar, President, Global Head of HR and Member of Management Council | ||
| Vivek Mittal, Interim Compliance Officer, General Counsel | ||
| Erez Israeli, Chief Operating Officer and Global Head of Generics & PSAI | ||
| Kalpana Morparia, Non-Executive Independent Director | ||
| J Moreau, Non-Executive Independent Director | ||
| Saunak Savla, IR Contact Officer | ||
| Deepak MBA, CEO Council | ||
| Ashok Ganguly, Non-Executive Independent Director | ||
| Anupam Puri, Non-Executive Independent Director | ||
| MBA MBA, CEO Council | ||
| Mukesh Rathi, Chief Digital and Information Officer |
RDY Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Dr Reddys a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.21 | ||||
| Return On Asset | 0.12 | ||||
| Profit Margin | 0.19 % | ||||
| Operating Margin | 0.25 % | ||||
| Current Valuation | (40.79 B) | ||||
| Shares Outstanding | 166.53 M | ||||
| Shares Owned By Institutions | 15.02 % | ||||
| Number Of Shares Shorted | 625.76 K | ||||
| Price To Earning | 31.58 X | ||||
| Price To Book | 3.70 X |
Currently Active Assets on Macroaxis
When determining whether Dr Reddys Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dr Reddys' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dr Reddys Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dr Reddys Laboratories Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Dr Reddys Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Dr Reddys Laboratories information on this page should be used as a complementary analysis to other Dr Reddys' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Complementary Tools for RDY Stock analysis
When running Dr Reddys' price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |
Is Dr Reddys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dr Reddys. If investors know RDY will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dr Reddys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.103 | Dividend Share 40 | Earnings Share 3.76 | Revenue Per Share 272.4618 | Quarterly Revenue Growth 0.066 |
The market value of Dr Reddys Laboratories is measured differently than its book value, which is the value of RDY that is recorded on the company's balance sheet. Investors also form their own opinion of Dr Reddys' value that differs from its market value or its book value, called intrinsic value, which is Dr Reddys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dr Reddys' market value can be influenced by many factors that don't directly affect Dr Reddys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dr Reddys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dr Reddys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dr Reddys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.